
Validea's guru fundamental report indicates that Gilead Sciences (GILD) receives a 100% rating based on their Twin Momentum Investor model, which is based on the strategy of Dashan Huang. The model combines fundamental and price momentum, and GILD passes all tests for fundamental momentum, twelve minus one momentum, and final rank. Huang's research suggests that stocks with strong fundamental momentum, particularly when combined with price momentum, tend to outperform the market.
Gilead Sciences Inc. (GILD), a large-cap growth stock within the Biotechnology & Drugs industry, has achieved a maximum 100% rating from Validea's Twin Momentum Investor model, based on Dashan Huang's published strategy. This exceptionally high score, where anything above 90% indicates strong interest, signifies that GILD fully aligns with the model's criteria for combining robust fundamental momentum and positive price momentum. The company passed all specific tests within this framework, including 'fundamental momentum', 'twelve minus one momentum', and the 'final rank'. Huang's research, underpinning this model, identified seven key fundamental variables (earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets, and net payout ratio) whose combined strength, when coupled with price momentum, has historically demonstrated the potential to generate market outperformance. The accompanying sentiment score of 0.85 for GILD is 'strongly positive' with a 'bullish' tone, reinforcing the quantitative model's favorable assessment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment